ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS

BACKGROUND: Low grade gliomas (LGGs) represent 10–15% of glial tumors in adults and while LGG patients have a better prognosis over high-grade gliomas, these cancers ultimately recur and transform to more aggressive tumors. Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in LGG, and when mutat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Peters, Katherine, Congdon, Kendra, Archer, Gary, Woodring, Sarah, Jaggers, Denise, Lipp, Eric, Healy, Patrick, Herndon, James, Soher, Brian, Vlahovic, Gordana, Johnson, Margaret, Randazzo, Dina, Desjardins, Annick, Friedman, Henry, Friedman, Allan, Ashley, David, Yan, Hai, Sampson, John
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Adult Clinical Trials–Immunologic
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847076/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.030
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы